A placebo‐controlled, randomized, double‐masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Neurology

• Publication date

  1989-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1212/WNL.39.8.1018PMID 2668784
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunological treatment of multiple sclerosis. II

  2004cited by this paper
• The Disability Status Scale for multiple sclerosis

  1989cited by this paper
• Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis

  1989cited by this paper
• Double blind controlled randomized study on azathioprine efficacy in multiple sclerosis. Preliminary results

  1988cited by this paper
• Immunotherapy of multiple sclerosis

  1988cited by this paper
• Clinical experience with azathioprine: The pros

  1988cited by this paper
• MR imaging in multiple sclerosis: comparison with clinical, CSF, and visual evoked potential findings.

  1988cited by this paper
• Magnetic resonance imaging and degree of disability in multiple sclerosis.

  1988cited by this paper
• A comprehensive protocol for clinical trials in multiple sclerosis which favored azathioprine and corticosteroid as a type of treatment for the chronic progressive phase

  1988cited by this paper
• A long-term double-blind controlled study on the effect of azathioprine in the treatment of multiple sclerosis.

  1988cited by this paper
• Magnetic resonance imaging and cognitive functioning in multiple sclerosis

  1987cited by this paper
• Evoked potentials predict the clinical changes in a multiple sclerosis drug study

  1987cited by this paper
• Cyclophosphamide 'pulses' in chronic progressive multiple sclerosis. A preliminary clinical trial.

  1987cited by this paper
• [Treatment of progressive and severe forms of multiple sclerosis using a combination of antilymphocyte serum, azathioprine and prednisone. Clinical and biological results. Comparison with a control group treated with azathioprine and prednisone only. 4-year follow-up].

  1987cited by this paper
• Combination of methylprednisolone pulse therapy and remission inducing drugs in rheumatoid arthritis.

  1987cited by this paper
• Methylprednisolone pulse therapy in conjunction with azathioprine in rheumatoid arthritis.

  1986cited by this paper
• Neuroepidemiology. Part II: Assessment of therapeutic trials

  1986cited by this paper
• Mechanisms in multiple sclerosis.

  1985cited by this paper
• An illness severity score for multiple sclerosis

  1984cited by this paper
• [Long-term immunosuppression in multiple sclerosis: evaluation of treatments begun before 1972].

  1984cited by this paper
• Therapeutic Trials in Multiple Sclerosis: Azathioprine a

  1984cited by this paper
• New diagnostic criteria for multiple sclerosis: Guidelines for research protocols

  1983cited by this paper
• Azathioprine in treatment of multiple sclerosis. Final results of a 41/2-year controlled study of its effectiveness covering 115 patients.

  1982cited by this paper
• Human Neurologic Function and the Aging Process †

  1980cited by this paper
• Immunosuppressive drugs in multiple sclerosis

  1980cited by this paper
• Immunological Treatment in Multiple Sclerosis

  1980cited by this paper
• Prolonged azathioprine treatment of non-remitting multiple sclerosis

  1979cited by this paper
• Longterm survival of lupus nephritis patients treated with azathioprine and prednisone.

  1978cited by this paper
• Prednisone and azathioprine compared to prednisone plus low-dose azathioprine and cyclophosphamide in the treatment of diffuse lupus nephritis.

  1976cited by this paper
• Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone.

  1975cited by this paper
• Cyclophosphamide or azathioprine in lupus glomerulonephritis. A controlled trial: results at 28 months.

  1975cited by this paper
• Long-term treatment of multiple sclerosis with azathioprine

  1973cited by this paper
• Multiple sclerosis unaffected by azathioprine in pilot study.

  1973cited by this paper
• Cooperative study in the evaluation of therapy in multiple sclerosis

  1970cited by this paper
• Long-term treatment of multiple sclerosis with corticotrophin.

  1967cited by this paper
• PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS

  1965cited by this paper
• USE OF AN ORAL CORTICOSTEROID IN THE TREATMENT OF MULTIPLE SCLEROSIS; A DOUBLE-BLIND STUDY.

  1965cited by this paper

• Inflammatory bowel disease therapies and demyelinating diseases: a practical guide to therapeutic benefit and risk

  2025cites this paper
• Updates on immunosuppressant safety and malignancy risk in patients with multiple sclerosis

  2025cites this paper
• Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta‐analysis

  2024cites this paper
• Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability?

  2024cites this paper
• A Real-World Experience of Azathioprine Versus First-Line Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis—A Prospective Cohort Study

  2023influential citation
• On an Important Residual in the GMANOVA–MANOVA Model

  2022cites this paper
• Hydroxychloroquine for Primary Progressive Multiple Sclerosis

  2021cites this paper
• Repurposing Domperidone in Secondary Progressive Multiple Sclerosis

  2021cites this paper
• Azathioprine for people with multiple sclerosis

  2021cites this paper
• Trials of Novel Therapies Specifically for Progressive MS

  2018cites this paper
• Case Studies of Autoregressive Linear Mixed Effects Models: Missing Data and Time-Dependent Covariates

  2018cites this paper
• Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis

  2018cites this paper
• Primary progressive multiple sclerosis: current therapeutic strategies and future perspectives

  2017cites this paper
• Mapping the effects of vitamin D in multiple sclerosis : a 3D perspective

  2017cites this paper
• Thérapeutiques et prise en charge de la sclérose en plaques

  2017cites this paper
• Therapie der primär und sekundär chronisch-progredienten MS

  2017cites this paper
• Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis

  2017cites this paper
• Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.

  2016cites this paper
• Mixed effects historical varying‐coefficient model for evaluating dose–response in flexible dose trials

  2016cites this paper
• Nonlinear Regression Modeling for Longitudinal Data and its Applications

  2015cites this paper
• Nonlinear Regression Modeling for Longitudinal Data and its Applications

  2015cites this paper
• The role of activated microglia in multiple sclerosis and clinically isolated syndromes : neuroimaging studies

  2015cites this paper
• Azathioprine versus Beta Interferons for Relapsing-Remitting Multiple Sclerosis: A Multicentre Randomized Non-Inferiority Trial

  2014cites this paper
• Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of Neurologists.

  2014cites this paper
• Personalized Management of Multiple Sclerosis

  2013cites this paper
• Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.

  2013cites this paper
• Immunotherapy of Multiple Sclerosis

  2013cites this paper
• Disease-modifying treatments for secondary progressive and progressive relapsing multiple sclerosis

  2013cites this paper
• Central nervous system B-cell lymphoma in multiple sclerosis.

  2012cites this paper
• WITHDRAWN: Guía para el tratamiento de pacientes con esclerosis múltiple: uso de inmunomoduladores e inmunosupresores

  2012cites this paper
• An autoregressive linear mixed effects model for the analysis of unequally spaced longitudinal data with dose‐modification

  2012cites this paper
• The Development of Primary Central Nervous System B-Cell Lymphoma in Multiple Sclerosis

  2011cites this paper
• [Oral cladribine for relapsing-remitting multiple sclerosis: another purine analogue or a genuine therapeutic innovation?].

  2010cites this paper
• Nocebo effects in multiple sclerosis trials: a meta-analysis

  2010cites this paper
• Cladribin-Tabletten bei schubförmiger Multipler Sklerose

  2010influential citation
• Influence of treatment in multiple sclerosis disability: an open, retrospective, non-randomized long-term analysis.

  2010cites this paper
• [Intravenous immunoglobulins in multiple sclerosis. An update].

  2009cites this paper
• Azathioprine for multiple sclerosis

  2009cites this paper
• Intravenöse Immunglobuline bei Multipler Sklerose

  2009cites this paper
• Back to the future for multiple sclerosis therapy: focus on current and emerging disease-modifying therapeutic strategies.

  2009cites this paper
• Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis

  2008cites this paper
• Azathioprine for multiple sclerosis.

  2007cites this paper
• sclerosis scheme for assessing drugs for multiple Problems with UK government's risk sharing

  2007cites this paper
• [CARIMS (Cancer Risk In Multiple Sclerosis) project: impact of long-term treatment].

  2007cites this paper
• Clinical Practice Guideline for Multiple Sclerosis November

  2007cites this paper
• Cancer et sclérose en plaques. Impact des traitements de fonds et présentation du projet CARIMS (Cancer Risk In Multiple Sclerosis)

  2007cites this paper
• Azathioprine. Safety profile in multiple sclerosis patients

  2007cites this paper
• Immunosuppression: promises and failures.

  2007cites this paper
• An autoregressive linear mixed effects model for the analysis of longitudinal data which show profiles approaching asymptotes

  2007cites this paper
• Intensive immunosuppression in multiple sclerosis FUTURE THERAPIES IN MULTIPLE

  2006cites this paper
• Intensive immunosuppression in multiple sclerosis

  2006cites this paper
• Trasplante autólogo de progenitores hematopoyéticos como opción terapéutica en la esclerosis múltiple

  2006cites this paper
• [Cost-utility analysis of relapsing-remitting multiple sclerosis treatment with azathioprine or interferon beta in Spain].

  2005cites this paper
• TREATMENTS FOR MULTIPLE SCLEROSIS

  2004cites this paper
• Other therapy options and future strategies for treating patients with multiple sclerosis

  2004cites this paper
• Azathioprine and methotrexate in multiple sclerosis.

  2004cites this paper
• Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity.

  2004cites this paper
• Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis

  2003cites this paper
• Disease-modifying therapies for multiple sclerosis

  2003cites this paper
• Mitoxantrone in progressive multiple sclerosis: when and how to treat?

  2003cites this paper
• [The BCTRIMS Expanded Consensus on treatment of multiple sclerosis: I. The evidences for the use of immunosuppressive agents, plasma exchange and autologous hematopoietic stem cell transplantation].

  2002cites this paper
• [Immunosuppressive medication in multiple sclerosis].

  2002cites this paper
• Disease modifying therapies in multiple sclerosis.

  2002cites this paper
• The Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and The MS Council for Clinical Practice Guidelines

  2002cites this paper
• Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

  2002cites this paper
• Multiple Sclerosis: Experience with Large Clinical Trials

  2001cites this paper
• Chapter 11 Multiple Sclerosis

  2001cites this paper
• [The natural history of multiple sclerosis].

  2000cites this paper
• Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials.

  2000cites this paper
• Steriods for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials

  2000influential citation
• Relapsing-Remitting Multiple Sclerosis

  2000cites this paper
• The immunological basis of current and novel therapies of multiple sclerosis.

  1999cites this paper
• The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment

  1999cites this paper
• Long-term open-trial of mizoribine with prednisolone in 24 patients with multiple sclerosis: safety, clinical and magnetic resonance imaging outcome.

  1999cites this paper
• Development of a multiple sclerosis functional composite as a clinical trial outcome measure.

  1999cites this paper
• A double-blind, placebo-controlled trial of extracorporeal photopheresis in chronic progressive multiple sclerosis

  1999cites this paper
• Multiple sclerosis: Immunotherapy

  1999cites this paper
• Causal inference in a clinical trial: a comparative example.

  1999cites this paper
• Azathioprine: clinical pharmacology and current indications in autoimmune disorders.

  1998cites this paper
• [Non-specific immunosuppression and multiple sclerosis].

  1998cites this paper
• Risk of Cancer in Patients with Myasthenia Gravis

  1998cites this paper
• Recommendations from the national multiple sclerosis society clinical outcomes assessment task force

  1997cites this paper
• Management of multiple sclerosis.

  1997cites this paper
• Emerging treatments in multiple sclerosis: Azathioprine and Mof etil

  1996cites this paper
• Risk of cancer from azathioprine therapy in multiple sclerosis

  1996cites this paper
• Combinations of drugs

  1996cites this paper
• Does a placebo-effect exist in clinical trials on multiple sclerosis? Review of the literature

  1996cites this paper
• Clinical scales for multiple sclerosis.

  1996cites this paper
• Meta-analysis of the placebo-treated groups in clinical trials of progressive MS

  1996cites this paper
• Multiple Sclerosis

  1996cites this paper
• Investigational drug therapies for treatment of multiple sclerosis

  1996cites this paper
• Strategies to Delay the Onset of Clinically Definite Multiple Sclerosis in Patients with Monosymptomatic Presentations of Optic Neuritis, Brainstem Syndromes or Myelopathy

  1996cites this paper
• Analysis and treatment of pathological blood-brain barrier dysfunction during experimental allergic encephalomyelitis.

  1996cites this paper
• Comparative evaluations of neuroperformance and clinical outcome assessments in chronic progressive multiple sclerosis: I. reliability, validity and sensitivity to disease progression

  1996cites this paper
• Multiple Sclerosis: New Approaches to Immunotherapy

  1996cites this paper
• The natural history of multiple sclerosis.

  1995cites this paper
• Immunotherapy in multiple sclerosis, Part 1.

  1995cites this paper
• Multiple sclerosis progression in a natural history study: Predictive value of cerebrospinal fluid free kappa light chains

  1995cites this paper
• Disease Modifying Therapies for Multiple Sclerosis

  1995cites this paper
• Design strategies in multiple sclerosis clinical trials

  1994cites this paper